Research programme: restenosis therapies - Avontec/BIOTRONIKAlternative Names: AVT-03
Latest Information Update: 07 Apr 2011
At a glance
- Originator Avontec
- Mechanism of Action Genetic transcription inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Coronary artery restenosis
Most Recent Events
- 22 Aug 2005 Preclinical trials in Coronary artery restenosis in Germany (Implant)